3T Biosciences: making TCR-based therapies more tumor selective

With $40 million in series A funding, 3T Biosciences is transitioning its TCR discovery platform into a pipeline of TCR-based bispecifics designed to overcome the modality’s selectivity and off-target toxicity challenges. 

The Stanford University spinout was founded in 2017 around a platform developed by professor Christopher Garcia for identifying HLA-presented tumor antigens, and T cell receptors (TCRs) that selectively target the short peptide sequences...